Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

NCT03149822 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03149822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03149822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
University of Colorado, Denver
Phase
Phase 1/2
Overall status
Completed
Start date
September 28, 2017
Completion date
February 16, 2024
Enrollment
45 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma